Table 1.

Baseline demographic, clinical, and radiological characteristics of the enrolled cohort.

Variablea
Age at ublituximab start (years)	47 (41–58)
Sex, n (%)
Male	11 (68.8)
Female	5 (31.2)

Comorbidities, n (%)
Yes	12 (75)
No	4 (25)

Smokers, n (%)
Yes	7 (43.8)
No	9 (56.2)

Education (years)	13 (8–13)
BMI (kg/m²)	26.9 (24.4–28.8)
Disease duration (months)	21.5 (5.3–153)
Naive to DMTs, n (%)	9 (56.3)
No. of prior DMTs	0 (0–2)
No. of relapses within 12 months before enrollment	2 (1–2)
No. of spinal cord lesions at baseline MRI	1 (1–3)
Lesion volume on T2-weighted sequences (baseline MRI) (mm3)	2,360.2 (1,484–5,348.7)
No. of patients with gadolinium-enhancing lesions at baseline MRI, n (%)	6 (37.5)
EDSS at the time of ublituximab start	4.5 (3.5–5.0)
Time on ublituximab (months)
3.5 (2–5.5)

^aData are presented as median (Q1–Q3) for continuous variables.

BMI, body mass index; DMTs, disease modifying therapies; EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; No, number.